PHXM vs. KLDO, LIAN, GHSI, MBRX, BCDA, MIRA, NH, CHRO, BGLC, and ERNA
Should you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Kaleido Biosciences (KLDO), LianBio (LIAN), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), BioCardia (BCDA), MIRA Pharmaceuticals (MIRA), NantHealth (NH), Chromocell Therapeutics (CHRO), BioNexus Gene Lab (BGLC), and Eterna Therapeutics (ERNA). These companies are all part of the "medical" sector.
Kaleido Biosciences (NASDAQ:KLDO) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.
Kaleido Biosciences received 54 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users.
Kaleido Biosciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500.
In the previous week, PHAXIAM Therapeutics had 2 more articles in the media than Kaleido Biosciences. MarketBeat recorded 2 mentions for PHAXIAM Therapeutics and 0 mentions for Kaleido Biosciences. PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.
81.6% of Kaleido Biosciences shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
PHAXIAM Therapeutics has higher revenue and earnings than Kaleido Biosciences.
Summary
PHAXIAM Therapeutics beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.
Get PHAXIAM Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PHAXIAM Therapeutics Competitors List
Related Companies and Tools
